Neurofibromatosis Type 1 Pipeline Analysis Report 2026

Neurofibromatosis type 1 (NF1) is an autosomal-dominant genetic disorder marked by nerve-sheath tumor development and diverse clinical features. According to Minhua Liao et al. (2025), approximately 1 in 3,000-3,500 individuals worldwide are affected, reflecting significant unmet clinical needs. According to the neurofibromatosis type 1 pipeline analysis, the NF1 therapeutic landscape includes multiple emerging therapies, notably MEK inhibitors, targeted small molecules, and innovative biologics progressing through clinical stages. The growing focus on precision medicine, improved genetic screening, and increased R&D investment is expected to accelerate drug development. These topic-specific factors are likely to drive substantial market growth in the coming years.

Report Coverage

The Neurofibromatosis Type 1 Pipeline Analysis Report gives comprehensive insights into neurofibromatosis type 1 therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for neurofibromatosis type 1. The neurofibromatosis type 1 report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The neurofibromatosis type 1 pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with neurofibromatosis type 1 treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to neurofibromatosis type 1.

Neurofibromatosis Type 1 Pipeline Outlook

Neurofibromatosis type 1 (NF1) is a genetic disorder caused by mutations in the NF1 gene, leading to abnormal nerve tissue growth. It presents with café-au-lait spots, neurofibromas, learning disabilities, and skeletal deformities. The condition arises from inherited or spontaneous mutations affecting the tumor suppressor protein neurofibromin, resulting in uncontrolled cell proliferation.

Neurofibromatosis type 1 treatments aim to manage symptoms, limit tumor growth, and enhance quality of life. Approaches include surgical tumor removal, targeted therapies such as kinase inhibitors, and supportive care for pain, skin, and neurological issues. In February 2025, mirdametinib (Gomekli, SpringWorks Therapeutics, Inc.) received FDA approval for adult and pediatric patients aged two years and older with symptomatic plexiform neurofibromas not amenable to complete resection, showing confirmed overall response rates of 41% in adults and 52% in pediatric patients, representing a notable advancement in NF1 therapy.

Neurofibromatosis Type 1 Epidemiology

The pipeline is gaining attention due to the disorder’s clinical complexity and tumor predisposition. According to Minhua Liao et al., 2025, NF1 is an autosomal-dominant genetic disorder caused by pathogenic variants in the NF1 gene, affecting approximately 1 in 3000 individuals globally. As per Rare Disease Advisor, NF1 is classified as a rare disease in both the United States and the European Union. As per Elisa Moya Kazmarek et al., 2024, the United Kingdom reports a prevalence of 1 in 4560 and an incidence of 1 in 2699, with nearly 50% of cases inherited. Said Farschtschi et al., 2025, report an incidence of approximately 1 in 3000 newborns in Germany.

Neurofibromatosis Type 1 - Pipeline Therapeutic Assessment

This section of the report covers the analysis of neurofibromatosis type 1 drug candidates based on several segmentations, including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The neurofibromatosis type 1 pipeline analysis report covers 50+ drug analyses based on drug classes:

• Small Molecules
• Monoclonal Antibodies
• Peptides

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration:

• Oral
• Parenteral
• Others

Neurofibromatosis Type 1 Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total neurofibromatosis type 1 clinical trials. Phase II leads with 53%, driven by advanced efficacy studies and expanding patient enrollment. Phase I holds 37%, supported by safety assessments and early biomarker evaluations. Phase III contributes 8%, reflecting pivotal trials and regulatory progress. This distribution underscores strong research momentum and potential market growth.

Neurofibromatosis Type 1 Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the neurofibromatosis type 1 pipeline analysis include small molecules, monoclonal antibodies, and peptides. The neurofibromatosis type 1 report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for neurofibromatosis type 1. MEK inhibitors are emerging as a key therapeutic class in the neurofibromatosis type 1 drug pipeline. For example, Koselugo (selumetinib), an oral selective MEK inhibitor, is approved in the US for adults with symptomatic, inoperable plexiform neurofibromas. It works by inhibiting the MAPK/ERK pathway, reducing tumour growth and associated pain, disfigurement, and functional impairment in NF1 patients.

Neurofibromatosis Type 1 Clinical Trials - Key Players

The report for the neurofibromatosis type 1 pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed neurofibromatosis type 1 therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in neurofibromatosis type 1 clinical trials:

• Healx Limited
• Shanghai Kechow Pharma, Inc.
• Pasithea Therapeutics Corp.
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Novotech (Australia) Pty Limited
• AstraZeneca
• Merck Sharp & Dohme LLC
• SpringWorks Therapeutics, Inc.
• PRG Science & Technology Co., Ltd.
• Novartis Pharmaceuticals

Neurofibromatosis Type 1 - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for neurofibromatosis type 1. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of neurofibromatosis type 1 drug candidates.

Drug: HLX-1502

HLX-1502 is an investigational, orally administered, first-in-class disease-modifying therapy designed to target the underlying molecular pathways driving neurofibromatosis type 1 (NF1), specifically aiming to reduce the growth and symptoms of plexiform neurofibromas. Sponsored by Healx Limited, this Phase 2, open-label, single-arm study is examining the safety, tolerability, and efficacy of HLX-1502 in patients aged 16 years and older, with an exploratory cohort including 12- to 15-year-olds. The trial assesses clinical and functional outcomes while monitoring adverse effects, with the study expected to be completed by January 2028.

Drug: HL-085

HL-085, also known as Tunlametinib, is a small-molecule MEK inhibitor being developed by Shanghai Kechow Pharma, Inc. for adult patients with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN). Tunlametinib targets the MAPK/ERK signaling pathway by inhibiting MEK kinase activity, thereby blocking downstream signals, suppressing tumor cell growth, and promoting apoptosis. Administered orally at doses of 6-12 mg twice daily on a 21-day continuous cycle, the Phase II study is evaluating its safety, pharmacokinetics, and efficacy to determine the optimal dose. The trial is ongoing, with expected completion by October 2028.

Drug: PAS-004

PAS-004 is an oral macrocyclic MEK 1/2 inhibitor being developed by Pasithea Therapeutics Corp. for adults with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas. This Phase 1/1b open-label study is examining the safety, tolerability, pharmacokinetics, and pharmacodynamics of PAS-004, focusing on identifying optimal dose levels and monitoring potential side effects. Administered once daily in 28-day cycles, the drug targets the MAPK/ERK pathway, aiming to reduce tumor growth and progression. The study includes regular clinical visits, MRIs, and blood tests, with an estimated completion in December 2027, enrolling approximately 56 participants.

Key Questions Answered in the Neurofibromatosis Type 1 Pipeline Insight Report

• Which companies/institutions are leading the neurofibromatosis type 1 drug development?
• Which company is leading the neurofibromatosis type 1 pipeline development activities?
• What is the current neurofibromatosis type 1 commercial assessment?
• What are the opportunities and challenges present in the neurofibromatosis type 1 pipeline landscape?
• What is the efficacy and safety profile of neurofibromatosis type 1 pipeline drugs?
• Which company is conducting major trials for neurofibromatosis type 1 drugs?
• Which companies/institutions are involved in neurofibromatosis type 1 collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in neurofibromatosis type 1?

Reasons To Buy This Report

The Neurofibromatosis Type 1 Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for neurofibromatosis type 1. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into neurofibromatosis type 1 collaborations, regulatory environments, and potential growth opportunities.